Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03879837 · ClinicalTrials.gov registry record · Phase 3
Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,902
- Enrollment target
NCT03879837 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 1,902 participants.
The verdict
NCT03879837, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,902 participants
- Enrollment target
Study Summary
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects with Asthma.
Interventions
- DRUG Fluticasone propionate pressurized metered dose inhaler
- DRUG Flovent HFA pressurized metered dose inhaler
- DRUG Placebo pressurized metered dose inhaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,902 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2021-07-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03879837
The ClinicalTrials.gov registry entry for NCT03879837 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,902 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fluticasone propionate pressurized metered dose inhaler is the first listed.
NCT03879837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03879837 about?
NCT03879837 is a clinical study titled "Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg". A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects with Asthma.
What is the current status of trial NCT03879837?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,902 participants. The study started on 2019-03-25. Estimated completion is 2021-07-09.
What interventions are being tested in trial NCT03879837?
The interventions under investigation include: Fluticasone propionate pressurized metered dose inhaler (DRUG), Flovent HFA pressurized metered dose inhaler (DRUG), Placebo pressurized metered dose inhaler (DRUG).
Who is sponsoring clinical trial NCT03879837?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.